Telomere length is maintained by the enzyme, telomerase, which has been linked to cellular immortality and tumour progression. However, the reasons for the high levels of telomerase found in human tumours are unknown. We have mapped the human telomerase RNA gene, (hTR), to chromosome 3q26.3 and show the hTR gene to be ampli®ed in four carcinomas, (2/33 cervix, 1/31 head and neck, 1/9 lung). In addition, increased copy numbers of the hTR locus was also observed in 97% of tumours. By in situ hybridisation, the histological distribution of high levels of hTR expression could be demonstrated in a lung tumour and its metastasis with hTR ampli®cation. These results are the ®rst report of genetic alterations involving a known component of telomerase in human cancer. Indeed, it is also the ®rst report of the ampli®cation of a speci®c locus within the chromosome 3q region frequently subject to copy number gains in human tumours. In addition, we also show for the ®rst time the histological distribution of the RNA component of telomerase in human tumours.
Introduction
The ends of mammalian chromosomes, the telomeres, are important for stabilising the chromosome during replication but because of the end replication problem these structures suer attrition in the absence of the enzyme telomerase (Bacchetti and Counter, 1995; Shay and Wright, 1996b) . As telomerase is inactivated before or soon after birth , telomeric attrition is experienced by all normal somatic cells studied and has been suggested as a mechanism by which human cells count replication events and limit their clonal proliferation by replicative senescence (Harley et al., 1990) . The presence of telomerase in immortal human cell populations and malignant tumours and its general absence prior to this stage, has led to the suggestion that cellular immortalization and telomerase reactivation are essential for the progression and clinical lethality of most human tumours, but not for their formation (Edington et al., 1995; Kim et al., 1994) .
Telomerase activity is essential for the immortal phenotype of certain human tumour cells with short telomeres but not for the proliferation of normal cells, suggesting that telomerase antagonists may be eective anticancer agents (Feng et al., 1995; Harley et al., 1990; Norton et al., 1996; Parkinson, 1996; Rhyu, 1995) . However, it is unclear whether high telomerase activity in human tumour cells is due to reactivation following genetic alteration when the cells become immortal following prolonged telomeric attrition, or whether the targets for human carcinogenesis are rare telomerase-positive stem cells which selectively expand during tumour progression as a result of a concomitant block in terminal maturation (Counter et al., 1992; Greaves, 1996; Kim et al., 1994; Shay and Wright, 1996a) . Nevertheless, it is generally agreed that genetic alterations to known components of telomerase in human tumours in vivo would support the reactivation hypothesis (Greaves, 1996; Shay and Wright, 1996a) . The reintroduction of an intact human chromosome 3 into a real carcinoma cell line inactivates telomerase, restoring telomeric attrition and senescence (Ohmura et al., 1995) and the E6 region of human papillomavirus 16 upregulates telomerase (Klingelhutz et al., 1996) . However, it is unclear whether either of these mecahnisms operate in vivo, or whether they are the result of a direct eect on telomerase.
Telomerase is composed of two proteins (of 80 and 95 kd in Tetrahymena (Collins et al., 1995) ) and an RNA component (Greider and Blackburn, 1985) , the human counterpart of which, (hTR), has recently been cloned (Feng et al., 1995) . hTR is often, but not always, overexpressed in immortal human cells and tumours. However, expression studies, like the biochemical detection of telomerase activity, do not distinguish between the selection and reactivation hypotheses Bacchetti and Counter, 1995; Feng et al., 1995; Greaves, 1996; Shay and Wright, 1996a,b) . A priori one might anticipate that hTR could act as an oncogene (Kipling, 1995) if the reactivation hypothesis were true and the concentration of hTR RNA in a particular tumour became rate limiting for telomerase activity. Point mutation and gene ampli®cation are known mechanisms of oncogene activation and genetic instability in solid tumours. Therefore, we decided to map the chromosomal position of the hTR gene to test whether it corresponded to regions of duplication and/or ampli®cation in human tumours in vivo. The results show that this is indeed the case. (ii), Partial metaphase spread showing hybridisation of the hTR probe (green) to both chromosome 3. The counterstain for the chromsomes is DAPI (blue) and (iii) shows inversion of the DAPI staining to give a G-like band pattern homologues, allowing localisation of the probe signal to 3q26.3. Ampli®cation of hTR in carcinomas. (b) Interphase cytogenetic analysis of hTR ampli®cation in a cervical carcinoma. The clusters of ampli®ed hTR sequences are visualised in green, the nuclei in red. (c) Interphase cytogenetic analysis of hTR ampli®cation in a lung tumour. The ampli®ed hTR sequences are visualised in green, the nuclei in red. Note the dispersed appearance of the ampli®ed hTR sequences within the nuclei in comparison to the cervix sample shown in (b). (d) Co-localisation of the hTR locus with the region of ampli®cation on chromsome 3 in a lung carcinoma. Labelled genomic DNA extracted from the lung tumour with a known ampli®cation of hTR, (c above), was cohybridised with the hTR probe to normal metaphase chromosomes. The images of chromosome 3 are shown with the hybridisation signal for the tumour DNA in red, (i), hTR probe in green, (ii), the DAPI stained chromosome 3 in blue, (iii), and the 3-colour merge is shown in (iv). (dv), shows a typical intensity plot for¯uorescence along the pro®le of chromsome 3 (blue trace) generating a visual representation of the hybridisation site for hTR (green trace) relative to genomic sequences ampli®ed in the lung tumour (red trace). Note the coincidence in peak¯uorescence for both the hTR probe and the chromosome 3 amplicon present in the tumour genome. (e) As a control, labelled genomic DNA extracted from a lung tumour without ampli®cation of hTR, was co-hybridisation with the hTR probe to normal metaphase chromosomes. The images for
Results

Chromosomal localisation of the hTR gene
The human telomerase RNA gene has recently been cloned and tentatively mapped to the long arm of chromosome 3 (Feng et al., 1995) . Due to the importance of the hTR gene and the high frequency with which chromosome 3 is implicated in the progression of some solid tumours (Arnold et al., 1996; Brzoska et al., 1995; Heselmeyer et al., 1996; Iwabuchi et al., 1995; Levin et al., 1994 Levin et al., , 1995 Ried et al., 1994; Speicher et al., 1995) , we decided to more precisely map the hTR locus. A P1 clone containing hTR sequences was obtained as described in the Methods and the chromosomal localisation determined by¯uorescence in situ hybridisation ( Figure  1a ). The hTR probe was localised by fractional length measurements (McLeod and Keith, 1996) , (Flpter), to the long arm of chromosome 3 with a mean Flpter value of 0.84 (number of chromosomes examined=23, standard error=0.02) which approximates to chromosome 3q26. The map position of hTR to chromosome 3q26.3 was con®rmed by DAPI banding of the hybridised chromosomes.
Ampli®cation of the hTR gene in solid tumours
Recent data from comparative genomic hybridisation (CGH), of a number of solid tumour types including cervix, lung and squamous cell carcinoma of the head and neck, (SCC-HN), show frequent copy-number gains and localised ampli®cations on the long arm of chromosome 3 (Arnold et al., 1996; Brzoska et al., 1995; Heselmeyer et al., 1996; Iwabuchi et al., 1995; Levin et al., 1994 Levin et al., , 1995 Ried et al., 1994; , whereas others such including breast and colon rarely show these chromosome 3 changes (Ried et al., 1995 . However, as yet no speci®c genes have been reported to be included within the amplicons. Having mapped hTR to chromosome 3q26.3, hTR gene copy number was quanti®ed by interphase cytogenetic analysis on frozen sections from 73 biopsies from cervix, lung and head and neck cancers using the cloned hTR sequences. Interestingly, the hTR gene was ampli®ed in four carcinomas, (2/33 cervix, 1/31 SCC-HN, 1/9 lung). Figure 1b and c show examples of hTR ampli®cation in one of the cervical carcinoma samples and the lung carcinoma. The pattern of hybridisation in the cervix and SCC-HN cancer indicated that the ampli®ed sequences were likely to be present as integrated blocks, (Figure 1b) . However, in the lung carcinoma, the hybridisation signal was dispersed over the nucleus which suggests an extrachromosomal origin for the ampli®ed hTR sequences in this tumour (Figure 1c) .
Ampli®ed regions may encompass large chromosomal segments. In order to examine the physical relationship between the map position of the hTR locus and the region ampli®ed in these tumours, genomic DNA isolated from two of the tumours (one cervix and the lung sample), was used as complex in situ probes, and reverse in situ hybridisation back onto normal metaphase chromosomes carried out as a double hybridisation with dierentially labelled hTR probe (Hoare et al., 1977; Joos et al., 1993) . Figure 1d (lung), and f (cervix) show typical intensity plots for uorescence along the pro®le of chromosome 3, generating a visual representation of the hybridisation site for hTR relative to the genomic sequences ampli®ed in the carcinomas. From the intensity pro®les shown in Figure 1d and f the regions ampli®ed on chromosome 3q in the tumour genomes can quite clearly be identi®ed and the peak¯uorescence intensities correspond to that of the site for the localisation of the hTR probe (Hoare et al., 1997) . Thus the hTR locus is within the most highly ampli®ed region in the tumour genomes and is therefore a candidate for the target locus ampli®ed on chromosome 3q.
As shown above, we have demonstrated amplification of the hTR locus in 4/73 tumours. Clearly it is important to determine how speci®c the ampli®cation is for hTR. The question is therefore, do any samples have an amplicon on chromosome 3q which excludes hTR, suggesting the presence of another locus near to hTR as the driver for ampli®cation. This issue was addressed in two ways, ®rstly, by an extension of the reverse in situ hybridisation approach, and secondly by carrying out interphase cytogenetics with chromosome 3q probes in the locality of hTR. Of the four tumours with hTR ampli®cation, (de®ned by FISH), sucient genomic DNA was available from three for reverse in situ hybridisation, and all three showed evidence of chromosome 3q ampli®cation by reverse in situ hybridisation, (examples of two of these are shown in Figure 1d and f). Of the 69 tumours without ampli®cation of hTR (de®ned by FISH), sucient genomic DNA was available from 41 for reverse in situ hybridisation, as an extension of the approach shown in Figure 1d ± g. Using this approach none of the 41 DNA samples from tumours without hTR amplification had evidence of ampli®cation of chromosome 3q material by reverse in situ hybridisation. The second approach was to carry out interphase cytogenetics using two P1 clones neighbouring the hTR locus. The P1 clone, RMC03P017, has a FLpter map position of 0.83 (3q25-q26, and contains the marker D3S1268) and chromosome 3 are shown with the hybridisation signal for the tumour DNA in red, (i), hTR probe in green, (ii), the DAPI stained chromosome 3 in blue, (iii) and the 3-colour merge is shown in (iv). (ev) shows a typical intensity plot for the¯uorescence along the pro®le of chromosome 3 (blue trace) generating a visual representation of the hybridisation site for hTR (green trace) relative to genomic sequences in the lung tumour (red trace). Note that no evidence of an ampli®cation on chromosome 3 is seen in the control hybridisations (ei) and (ev) in comparison to (di) and (dv) above. (f) shows co-localisation of the hTR locus with the region of ampli®cation on chromosome 3 in a cervical carcinoma. (f) shows a typical intensity plot for¯uorescence along the pro®le of chromosome 3 (blue trace) generating a visual representation of the hybridisation site for hTR (green trace) relative to genomic sequences ampli®ed in the cervical carcinoma (red trace). Note the coincidence in peak¯uorescence for both the hTR probe and the chromosome 3 amplicon present in the tumour genome. (g) shows the intensity plot for the control hybridisation with DNA from a cervical carcinoma without ampli®cation of the hTR locus. (h) shows interphase cytogenetic analysis of cervix sample, C47, with the P1 clones: (i) RMC03P017; (ii) hTR; (iii) RMC03P061 the P1 clone RMC03P061, has a FLpter map position of 0.92 (3q28, and contains the gene Bc16) (LBL/ UCSF Resource for molecular Cytogenetics, http:// rmc-www.lbl.gov/). hTR has a FLpter map position of 0.84 and using double hybridisations on lymphocyte metaphase spreads, the signal for marker RMC03P017 which lies closest to hTR cannot be resolved from that of hTR suggesting they lie close together on chromosome 3 (data not shown). Sucient sections were available to carry out hybridisations on the two cervix samples, C47 and C60 which have ampli®cation of the hTR gene. Neither RMC03P017 or RMC03P061 were ampli®ed and examples of the hybridisations with the three P1 clones (hTR, RMC03P017 and RMC03P061) on cervix sample C47 are shown in Figure 1h . Thus by a combination of interphase cytogenetics and reverse in situ hybridisation, the only 3q amplicons detected cover hTR, consistent with the suggestion that hTR is a good candidate for the target locus ampli®ed on chromosome 3q.
Copy number gains of the hTR locus in solid tumours
During the analysis of the high level ampli®cations described above, it became apparent that in addition to these tumours, many samples had subpopulations of nuclei with a greater than normal hTR copy number. Therefore, in order to quantitate hTR copy number, a group of tumours showing high quality hybridisations and good morphology were selected for further study using previously established criteria (Murphy et al., 1995a) . From Table 1 it can be seen that of 18 SCC-HN biopsies, 17 showed subpopulations of nuclei (ranging from 18 ± 90%), with more than two hybridisation sites for hTR per nucleus. Of 12 cervix biopsies, all contained subpopulations of nuclei (ranging from 14 ± 84%) with greater than two hybridisation sites for hTR per nucleus. The range in number of hTR signals per nucleus in each tumour also varied, and although some of this variation is likely to be due to nuclear truncation (Murphy et al., 1995a) nuclei with up to a maximum of 10 copies of hTR were detected (Table 1) .
Possible mechanisms of increased hTR copy number in these samples include polysomy and isochromosome formation. To obtain information on the mechanism and indirectly to evaluate whether structural changes may occur on chromosome 3, the ratio of hTR copies to chromosome 3 centromeric sequences in each tumour was determined. A ratio of one suggests equality of hTR gene copies and chromosome 3 centromeric sequences, a ratio of 1.5 suggests a gain of one copy of hTR relative to chromosome 3 centromere. From Figure 2 it can be seen that seven out of 18 SCC-HN and one out of 12 cervical carcinomas hava a ratio of hTR signals to chromosome 3 centromere signals greater than 1.5 indicating a structural change such as isochromosome 3q or a duplication of part 3q encompassing hTR. Indeed, preliminary data from FISH analysis of SCC-HN cell lines with the hTR probe in our laboratory support these interpretations (data not shown). The remaining SCC-HN biopsies and cervical carcinomas have a ratio between 0.5 ± 1.5 and so increased hTR copy number in these tumours is likely to be due to polysomy of chromosome 3.
In situ detection of the essential RNA component of telomerase
To examine expression of hTR we used in situ hybridisation with a riboprobe labelled with 35 S. This 
Eighteen SCC-HN biopsies, (HN1 ± 18) and 12 cervical carcinomas, (C1 ± 12), were analysed for hTR copy number by FISH. For each sample, the mean hTR copy number per nucleus, the % of nuclei within each biopsy with more than two hybridization sites, (%42), and the minimum and maximum number of hybridization sites per nucleus, are shown. More than 10% of the nuclei had to show greater than two signals for the hTR probe, to be evaluated as having a gain of hTR sequences, (Murphy et al., 1995a) Figure 2 Gains in hTR copy number in cervix cancers and squamous cell carcinomas of the head and neck (SCC-HN). The ratio for hTR copy number to chromosome 3 centromericsequence copy number is shown for 18 SCC-HN biopsies and 12 cervix biopsies. A ratio of one suggests equal numbers of hTR gene copies and chromosome 3 centromeric sequences, a ratio of 1.5 suggests a gain of one copy of hTR relative to chromosome 3 centromere allowed us to examine the histological distribution of the RNA component of the telomerase enzyme. We have concentrated on two individuals with lung cancer, L2, is hTR ampli®ed and is shown in Figure  1c , with the reverse in situ data shown in Figure 1d . L3 does not have hTR ampli®cation and is shown in Figure 1e . From the tumour archives we were able to obtain sections from both the primary tumours and a lymph node metastasis from both individuals. Thus in total four tumour blocks were examined. From Figure  3 it can be seen that the histological distribution of essential RNA component of telomerase can be detected by in situ hybridisation and that high levels of telomerase RNA expression are found in a lung tumour and its metastasis with ampli®cation of the hTR gene (Figure 3a , c and e) and not in a lung tumour and its metastasis without hTR ampli®cation (Figure 3f ). In addition, within a tumour with hTR ampli®cation, regions of high levels of expression are clearly distinguishable from those with low or undetectable (Figure 3a, c and e) . Thus, the normal squamous epithelium is negative as in an area of squamous metaplasia of the bronchial epithelium (Figure 4d ). Interestingly, high levels of telomerase RNA expression are maintained in a lymph node metastasis from a primary tumour with high levels of expression ( Figure 4a , c and e). Expression is nuclear localised and detected in all tumour cells. 
Discussion
Telomere stabilisation through telomerase activity is probably critical for survival and sustained replication of tumour cells and this with its almost ubiquitous expression in tumour cells make telomerase inhibition an attractive anticancer strategy (Bacchetti and Counter, 1995; Norton et al., 1996; Parkinson, 1996; Shay and Wright, 1996b; Wright and Shay, 1995; Rhyu, 1995) . Indeed, the recent demonstration that telomerase inhibition through the expression of antisense hTR transcripts leads to cell crisis supports telomerase antagonism as an important new strategy for the suppression of tumour growth (Feng et al., 1995) . However, while many tumours that have been assayed for telomerase activity (Bacchetti and Counter, 1995; Shay and Wright, 1996b) , it is still unclear whether high levels of telomerase are a result of genetic reactivation or to the selection of pre-existing telomerase positive cells (Greaves, 1996; Shay and Wright, 1996a) . At present progress is limited by a lack of molecular reagents but the human telomerase RNA component has been cloned (Feng et al., 1995) . Since the RNA component is a proven target for antagonism and subject to novel oligonucleotide-based gene therapeutics (Feng et al., 1995; Norton et al., 1996) , it is clearly important to investigate this gene in human tumours.
Mapping the hTR locus to chromosome 3q26.3 places it within a region of the human genome frequently subject to both localised ampli®cations and whole arm or whole chromosome gains in solid tumours (Arnold et al., 1996; Brzoska et al., 1995; Heselmeyer et al., 1996; Iwabuchi et al., 1995; Levin et al., 1994 Ried et al., 1994; Speicher et al., 1995) . We used interphase cytogenetics to study the hTR locus as the most direct method to quantitate hTR copy number per tumour cell and the optimal approach to analyse the distribution of genetic change in histologically de®ned areas (Murphy et al., 1995a,b) . These are important considerations for tumour heterogeneity and the selection of cells with an immortal phenotype. We found the hTR gene to be ampli®ed in four out of 73 carcinomas analysed and this is the ®rst report on the ampli®cation of a speci®c locus within the chromosome 3q region and the ®rst description of a genetic alteration of a known component of human telomerase in vivo. Indeed, hTR is a promising candidate for the target locus ampli®ed on chromosome 3q given the role of telomerase in cellular senescence (Kipling, 1995; Wright and Shay, 1995) . Although a neighbouring locus cannot at this stage be ruled out, no region of chromosome 3q ampli®cation was detected in 41 tumours examined which did not have ampli®cation of hTR. Moreover, the co-localisation of peak¯uorescence for the hTR probe and the chromosome 3 ampli®cation unit in the lung and cervical carcinomas as shown in Figure 1d and f demonstrates how close hTR lies to the centre of the ampli®ed sequences and supports hTR as a candidate locus, as does the interphase cytogenetic analysis of hTR ampli®ed tumours with neigbouring markers.
It has been noted that telomerase RNA expression can be detected in the absence of telomerase enzyme activity and indeed upregulation of the RNA component may be an early event in tumour progression Blasco et al., 1995 Blasco et al., , 1996 Feng et al., 1995) . Given that telomerase is a multi-component enzyme, genetic events leading to reactivation of the RNA element may occur prior to reactivation of the protein elements (Collins, 1996) , and we have presented a number of genetic events such as ampli®cation and isochromosome formation which may contribute to this. Once the genes for the protein elements of human telomerase have been cloned and mapped, the temporal sequence and combination of events leading to telomerase up regulation can be analysed in full. Interestingly, telomerase RNA is overexpressed in a number of tumours which would be consistent with hTR being an active component of the amplicon . Therefore, it was important to determine whether a tumour with hTR ampli®cation expressed the telomerase RNA component, as this would provide some evidence to support the idea that the ampli®ed hTR gene has some biological eect. To examine expression of hTR, we used in situ hybridisation. This allowed us to examine for the ®rst time the histological distribution of the essential RNA component of the telomerase enzyme in human tumours. This is an important issue in examining the role for telomerase in the development of immortal or metastatic clones from a telomerase negative solid tumour, and central to clarifying whether the selection of telomerase positive cells or telomerase activation occurs in tumours (Shay and Wright, 1996a,b; Greaves, 1996) . Thus, the in situ detection of the telomerase RNA component complements the interphase cytogenetic approach used to study the hTR gene. Interestingly, high levels of telomerase RNA expression were found in a lung tumour and its metastasis with ampli®cation of the hTR gene (Figure 3) , suggesting that the expression is a stable phenotype. An advantage of the in situ detection of the telomerase RNA component, is that its histological distribution can be assessed. The data shown in Figure 3 clearly demonstrates the dierential in expression between the tumour and adjacent normal tissue, with telomerase RNA expression detected in all the tumour cells and nuclear localised. In addition, the lung tumour studied which had high levels of expression in areas of tumour, also had regions of squamous metaplasia, a potential precursor lesion to lung cancer, and this did not have detectable levels of expression. Thus, in the future it may be possible to trace the evolution of immortal sub-clones within tumours and detect rare clones in apparently benign lesions or normal tissue and identify the cell type.
In addition to the ampli®cation of the hTR locus, increased copies of hTR were found in 97% of cervical carcinomas and SCC-HN studied in detail and this was likely to be due to polysomy of chromosome 3 and isochromosome 3q formation. These data are consistent with the chromosome 3 data from karyotypic and CGH analysis of SCC-HN and cervical cancer Hermsen et al., 1996; Heselmeyer et al., 1996; Speicher et al., 1995; Sreekantaiah et al., 1994; Van Dyke et al., 1994) and suggest dysregulation of hTR expression may occur by a number of genetic routes including ampli®cation, polysomy and isochromosome 3q formation. Thus, possible mechanisms of telomerase activation and escape from senescence, include imbalance between gain of hTR copies and the loss or titration out of telomerase repressors, for example isochromosome 3q would result in loss of the chromosome 3p repressor, (Ohmura et al., 1995) with a gain of one copy of hTR. Furthermore, ampli®cation of hTR may titrate out other repressors. In the future it will be important to expand our studies to link the genetic alterations at and around the hTR locus with the expression of the telomerase RNA component as this will help clarify by which mechanisms telomerase activity is ultimately regulated in tumour cells.
The studies presented here used in the main, in situ technologies to analyse the hTR locus and its expression, and clearly show the importance of heterogeneity within the tumour sections, therefore new quantitative in situ approaches to telomerase RNA expression and activity will have to be developed to investigate the relationship between the hTR gene, its expression, and telomerase activity. However, genetic events altering the expression of hTR or the expression of the RNA component of telomerase, may mark cells in the early stages of disease progression with the potential to become immortal through a telomerase activation pathway, prior to the detection of the telomerase activity, and may be of more prognostic use than the enzyme activity itself, which is present in most solid tumours (Shay and Wright, 1996b) . Indeed, the in situ approach we have taken to analyse the hTR locus and its expression is ideally placed to be developed within the diagnostic setting.
A strength of our analysis of the hTR locus and its expression is that all the alterations described have been identi®ed in tumour biopsy samples rather than cell lines. Now that we have described a series of molecular changes involving a component of the telomerase ribonuclear enzyme we can start to build representative cell line models to understand the role of these genetic changes in the regulation of telomerase activity and test anti-telomerase therapies under clinically relevant conditions.
Materials and methods
Tissue samples
Seventy-three carcinomas of the head and neck, lung and cervix were analysed in the study and 5 m frozen sections were available from previous studies. Sections were stored at 7208C until use. Of the 33 cervical carcinomas, 32 were squamous and one an adenocarcinoma. Of the 31 head and neck carcinomas, 30 were squamous, one a papillary adenocarcinoma. All nine lung carcinomas were squamous non-small cell. All four carcinomas which had amplification of hTR were squamous.
Cloning of hTR
A genomic clone containing the human telomerase RNA gene was identi®ed by screening the Du Pont Merck Pharmaceutical Company human foreskin ®broblast P1 library DMPC-HFF#1-279-B8, clone name 9913. Screening was carried out by Genome Systems Inc, St Louis, Missouri, using PCR primers directed to the hTR genomic sequence (Feng et al., 1995) , primer hTRg (a 20 bp oligo starting at base 430 of the published sequence), and primer hTRh (a 21 bp oligo corresponding to bases 691 ± 711 of the published sequence). Clone 9913 was con®rmed as containing hTR sequences by the sequencing of PCR products generated using clone 9913 as a template for primers hTRg and hTRh and primers hTRe, (a 20 bp oligo starting at base 404 of the published sequence) and hTRf, (a 20 bp oligo corresponding to bases 637 ± 656 of the published sequence).
FISH analysis
Probe labelling, in situ hybridisation and probe detection were as previously described (Murphy et al., 1995a; Soder et al., 1995) using the Hybaid Omnislide system (Hybaid Ltd, Teddington, UK). Chromosome 3-speci®c centromeric probes were purchased from Appligene-Oncor (Durham, UK) and Cytocell Ltd (Banbury, UK). Chromosome 3p telomere probe was purchased from Appligene-Oncor (Durham, UK). Fluorescence was analysed and images captured using confocal microscopy or a CCD camera. Original unedited images were stored on optical disks and have been retained. Normal lymphocyte interphase nuclei and metaphases were used as hybridisation controls to ensure probe speci®city and that the hybridisation eciency was greater than 95%. Chromosome 3 and hTR gene copy number in individual cancer cells was determined by FISH analysis of interphase nuclei. Quantitative evaluation of hybridisations was carried out on 50 nuclei according to previously described criteria (Murphy et al., 1995a,b) . For tumours described in Table 1 , more than 10% of the nuclei had to show greater than two signals for the hTR probe, to be evaluated as having a gain of hTR sequences (Murphy et al., 1995a) . A tumour was de®ned as having ampli®cation of the hTR locus when the density of hybridisation signal precluded the counting of individual hybridisation spots (this was greater than 10 hybridisation sites per nucleus), and the pattern of hybridisation was consistent with ampli®cation as discussed previously (Murphy et al., 1995a,b; Coutts et al., 1993; Robertson et al., 1996) . In addition normal areas of tissue within the tumour blocks served as internal controls. Speci®city of the P1 probe 9913 for detection of hTR ampli®cation was con®rmed by Southern blot using a small PCR generated probe corresponding to TRC3 sequences in hTR (Feng et al., 1995) (data not shown). The two chromosome 3q P1 clones, RMC03P017 and RMC03P061, were obtained from the LBL/UCSF Resource for molecular Cytogenetics, (http:// rmc-www.lbl.gov/). The P1 clone, RMC03P017, has a FLpter map position of 0.83, a band map position of 3q25-q26 and contains the marker D3S1268. The P1 clone RMC03P061, has a Flpter map position of 0.92, a band map position of 3q28 and contains the marker Bcl6 (LBL/UCSF Resource for molecular Cytogenetics, http://rmcwww.lbl.gov/). hTR has a FLpter map position of 0.84 and a band map position of 3q26.3 as shown in this study. Flpter is the distance from the probe location to the end of the short arm of a chromosome divided by the total length of the chromosome (McLeod and Keith, 1996; Hoare et al., 1997) . Published Flpter maps are available from the Resource for Molecular Cytogenetics at Lawrence Berkeley National Laboratories and the University of California, San Francisco (Internet connection, http://rmc-www.lbl.gov/) and also in Bray-Ward and colleagues (Bray Ward et al., 1996) .
Reverse in situ hybridisation (REVISH) using genomic DNA as a probe (Hoare et al., 1997) Co-localisation of tumour amplicons with the position of the hTR locus on chromosome 3 was carried out by cohybridising labelled tumour DNA with the cloned hTR probe (Hoare et al., 1997; Joos et al., 1993) . Analysis of digitised images was carried out using IPLab Spectrum software with SmartCapture extensions from Digital Scienti®c Ltd (Cambridge UK). GraphPolygon was used to produce an intensity plot of¯uorescence along the pro®le of the chromosome where the width of the chromosome was determined in pixels and the average intensity over the width plotted (Hoare et al., 1997; McLeod and Keith, 1996) . Thus, a visual representation for the localisation of hTR on chromosome 3 relative to genetic imbalances present in the test tumour is generated. At least four metaphase spreads were examined and representative¯uorescence intensity plots shown in Figure  1d ± g.
Detection of hTR gene expression by in situ hybridisation
Paran sections (5 m), were subjected to RNA in situ hybridisation using 35 S-labelled antisense or sense hTRspeci®c riboprobes (Fitzpatrick et al., 1990) . In order to generate the riboprobe vectors, sequences corresponding to TRC3 (Feng et al., 1995) were cloned into pCR-Script (Stratagene Ltd, Cambridge, UK), and the inserts sequenced. Autoradiographic exposures were from 1 to 3 weeks. Within each experiment, sections were hybridised with the same batch of probe, exposed for the same length of time and processed together.
